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Purpose: To synthesize and characterize novel thiazolidinone derivatives and screen them for 
antitubercular activity. 
Methods: A series of twelve novel thiazolidinones 4a-l have been synthesized by cyclocondensation of 
various Schiff bases of amino thiadiazole with thioglycollic acid. Various Schiff bases 3a-l were 
synthesized by condensation of 2-amino-5-aryl-5H-thiazolo[4,3-b]-l,3,4-thiadiazole with various aryl 
aldehydes. The synthesized compounds were characterized by FTIR, 1H-NMR, 13C-NMR and mass 
spectrometry. Docking studies were carried out for the synthesized compounds which were also 
evaluated for in vitro anti-tubercular activity at a concentration of 0.1 – 100.0 μg/mL by Microplate Blue 
Alamar Assay method. Pyrazinamide and streptomycin were used as standard antitubercular agents. 
Results: The synthesized compounds showed good docking score, compared to standard drugs. Two 
of the compounds (labelled 4f and 4i) showed higher antitubercular activity than the standards 
(pyrazinamide and streptomycin) while compounds four others compounds (labeled 4b, 4c, 4e, 4h, 4k 
and 4l) showed comparable activity to pyrazinamide but greater activity than streptomycin.  
Conclusion: We report the successful synthesis of novel thiazolidinones, as well as their spectral 
characterization, docking properties and in vitro antitubercular activities which, for some, are superior to 
currently used anti-tubercular agents.  
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INTRODUCTION 
 
Despite the ready availability of effective 
treatments, tuberculosis remains a major 
public health threat worldwide. The 
emergence of drug-resistant strains of 
Mycobacterium tuberculosis, particularly 
multiple drug resistant strains [1-4], has 
complicated treatment protocols and raises 
the concern that tuberculosis may once again 
become an incurable disease. For this 
reason, it is critical to discover new drugs 
acting with a mechanism different from those 
presently in use. 
 
Small ring heterocycles containing nitrogen, 
sulfur and oxygen have been under 
investigation for a long time because of their 
important medicinal properties. Among this 
type of molecules, 1,3,4-thiadiazoles and  4-
thiazolidinones were shown to have various 
important biological activities such as 
antibacterial, antifungal, antiviral, diuretic, 
tuberculostatic, anti-HIV, antihistaminic, 
anticancer, anticonvulsant, anti-inflammatory 
and analgesic properties [5-12].  
 
In order to further assess the 
pharmacological profile of this class of 
compounds, it was thought worthwhile to 
synthesize some new congeners of 
heterocycles by incorporating thiadiazole and 
thiazolidinone moieties in a single molecular 
framework. The present work deals with the 
synthesis of these compounds as well as 






Analytical grade solvents and commercially 
available reagents were used without further 
purification. All chemicals were obtained from 
Spectrochem Ltd (Mumbai, India). Column 
chromatography was carried out over silica 
gel (60 - 120 mesh), purchased from Sisco 
Research Laboratories Pvt Ltd. Mumbai, 
India. Melting point was determined in a 
programmable melting point apparatus 
(Servewell Instruments Pvt Ltd). Fourier 
transform infrared spectroscopy (FTIR) in KBr 
disk were recorded from 4000 to 400 cm-1 on 
a Shimadzu FT-IR spectrometer (model no. 
00518). 1H and 13C nuclear magnetic 
resonance (NMR) spectra were recorded on 
AMX 400-MHz and 500-MHz Bruker 
spectrometer in DMSO-d6 or CDCl3 using 
tetramethylsilane (TMS) as an internal 
standard. Chemical shifts are given in δ 
relative to TMS while the coupling constants 
are given in Hz. Mass spectra were recorded 
using Agilent 1100 MSD spectrometer in 




All the compounds were synthesized 
according to the scheme shown in Figure 1. 
The purity of the compounds was determined 
on TLC plates using silica gel G as a 




thiazolo[4,3-b]-l,3,4-thiadiazole (1)  
 
2-amino-5-aryl-5H-thiazolo[4,3-b]-l,3,4-
thiadiazoles were prepared according to the 
procedure reported in the literature [13]. An 
aromatic aldehyde (0.02M) and thioglycolic 
acid (0.02M) were mixed, and after 10-15 
min. Thiosemicarbazide (0.022M) was added; 
then 10 mL of concentrated H2SO4 was 
added in portions upon cooling. The mixture 
was homogenized and left for 18 - 24 h at -20 
°C. The reaction mass was treated with 30 - 
50 g ice, the precipitated solid decanted, 
water added, and the resulting suspension 
neutralized with 40 % NaOH solution. The 
synthesized compound was recrystallized 
from aqueous dioxane solution. 
 
General procedure for the synthesis of 
compounds 3a-3l 
 
To a stirred solution of compound 1(0.01M) in 
ethanol (50 ml) containing sulphuric acid (2 
ml) was added appropriate aromatic 
aldehyde (0.01M) and the mixture refluxed for 
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Fig 1: Synthesis of novel thiazolidinone derivatives 4a-4l 
 
4 - 6 h on a water bath. The separated solid 
was filtered and recrystallized from ethanol to 
give compounds 3a-3l.  
 
General procedure for the synthesis of 
compounds 3a-3l 
 
To a stirred solution of compound 1(0.01M) in 
ethanol (50 ml) containing sulphuric acid (2 
ml) was added appropriate aromatic 
aldehyde (0.01M) and the mixture refluxed for 
4 - 6 h on a water bath. The separated solid 
was filtered and recrystallized from ethanol to 
give compounds 3a-3l.  
 
General procedure for the synthesis of 
compounds 4a-4l 
 
To a stirred solution of the particular 5-
phenyl-N-[(substituted) phenylmethylene][1,3] 
thiazolo[4,3-b][1,3,4]thiadiazol-2-amine 
(Schiff base 3a-l, 0.01M) and thioglycollic 
acid (0.01M) in DMF (30 ml). The reaction 
mixture refluxed for 6 h and the solid 
obtained after removal of the solvent was 
crystallized from benzene to give compounds 
4a-4l.  
 
Evaluation of anti-tubercular activity 
 
The antimycobacterial activity of the 
































 4 hrs reflux
6 hrs reflux
R1= -H, R2= -H, (3a)
R1= -H, R2= 2-Cl, (3b)
R1= -H, R2= 4-Cl, (3c)
R1= 4-CH3, R2= H, (3d)
R1= 4-CH3, R2= 2-CH3, (3e)
R1= 4-CH3, R2= 4-CH3, (3f)
R1= 4-OH, R2= -H, (3g)
R1= 4-OH, R2= 2-OH, (3h)
R1= 4-OH, R2= 4-OH, (3i)
R1= 4-N(CH3)2, R2= H, (3j)
R1= 4-N(CH3)2, R2= 2-OCH3, (3k)
R1= 4-N(CH3)2, R2= 4-OCH3, (3l)
R1= -H, R2= -H, (4a)
R1= -H, R2= 2-Cl, (4b)
R1= -H, R2= 4-Cl, (4c)
R1= 4-CH3, R2= H, (4d)
R1= 4-CH3, R2= 2-CH3, (4e)
R1= 4-CH3, R2= 4-CH3, (4f)
R1= 4-OH, R2= -H, (4g)
R1= 4-OH, R2= 2-OH, (4h)
R1= 4-OH, R2= 4-OH, (4i)
R1= 4-N(CH3)2, R2= H, (4j)
R1= 4-N(CH3)2, R2= 2-OCH3, (4k)
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assessed against M. tuberculosis H37Rv 
(ATCC 2729411) using the Microplate Alamar 
Blue Assay (MABA) [14,15]. This 
methodology is non-toxic, uses thermally 
stable reagent, and shows good correlation 
with proportional and BACTEC radiometric 
methods [16], The activity was expressed as 
minimum inhibitory concentration (MIC) in 
μg/mL. The drug concentration tested were in 
the range 0.1 – 100.0 μg/mL. A blue color in 
the well was interpreted as absence of 
bacterial growth, and pink color was scored 
as growth. MIC (minimal inhibition 
concentration) was defined as the lowest 
drug concentration, which prevented a color 
change from blue to pink. Streptomycin and 





Docking was carried out for the synthesized 
compounds 3a-l, and 4a-l using Hex 5.1 
software Scotland, UK. Molecular docking 
involves the following steps using Hex 5.1 
software: 
1. Identify a target protein 2YES from 
the protein data bank. 
2. Download PDB FILE (text) and save 
in Example Folder of Hex 5.1. 
3. Draw all the ligands using 
ChemSketch software. 
4. Generate 3-D view (SDF format) and 
convert it into MOL file. 
5. Convert into PDB format by using 
Swiss PDB viewer and save it. 
6. Open Hex 5.1 software, select 





The physicochemical parameters of the 
synthesized compounds, including melting 
point, are shown in Table 1 while docking 
score and anti-tubercular results are listed in 
Tables 2 and 3, respectively. In Schiff base 
series compounds 3f, 3h and 3i showed 
good antitubercular activity compared to 
standard streptomycin. In Thiazolidinone 
series compounds 4f and 4i showed good 
antitubercular activity compared to both 
standards pyrazinamide and streptomycin 
and compounds 4b, 4c, 4e, 4h, 4k, 4l 
showed similar activity compared to standard 
pyrazinamide but showed better than 
standard streptomycin. The detail spectral 




(3a): FTIR (KBr) cm-1: 3115 (Ar C-H), 2960 
(C-H), 2880 (C-H thiazole), 1590 (-N=CH), 
702 (C-S-C); 1H NMR chemical shifts at ( 400 
MHz, CDCl3, δ ppm): 11.14 (s, 1H, CH), 8.14 
(s, 1H, -N=CH), 7.98 (s, 1H, CH), 7.30-7.68 
(m, 10H, Ar-H);  MS spectrum, m/z: 324[M+1] 
+; Anal. Calcd for C17H13N3S2: C (63.13), H 
(4.05), N (12.99). Found: C (63.11), H (4.01) 
and N (12.95).  
    
N-[(1E)-(2-chlorophenyl)methylene]-5-
phenyl[1,3]thiazolo[4,3-b][1,3,4]thiadiazol-
2-amine (3b): FTIR (KBr) cm-1:  3110 (Ar C-
H), 2890 (C-H), 2810 (C-H thiazole), 1598 (-
N=CH), 682 (C-S-C); 1H NMR chemical shifts 
at ( 400 MHz, CDCl3, δ ppm): 11.05 (s, 1H, 
CH); 8.04 (s, 1H, -N=CH); 7.86 (s, 1H, CH); 
7.40-7.75 (m, 9H, Ar-H); MS spectrum, m/z: 




2-amine (3c): FTIR (KBr) cm-1: 3095 (Ar C-
H); 2930 (C-H); 2820 (C-H thiazole), 1582 (-
N=CH), 710 (C-S-C); 1H NMR chemical shifts 
at ( 400 MHz, CDCl3, δ ppm): 11.10 (s, 1H, 
CH), 8.20 (s, 1H, N=CH), 7.90 (s, 1H, CH), 
7.15-7.72 (m, 9H, Ar-H); MS spectrum, m/z: 




b][1,3,4]thiadiazol-2-amine (3d): FTIR (KBr) 
cm-1: 3157 (Ar C-H), 2929 (C-H), 2850 (C-H 
thiazole), 1598 (-N=CH), 705 (C-S-C); 1H 
NMR chemical shifts at ( 400 MHz, CDCl3, δ 
ppm): 10.30 (s, 1H, CH), 8.37 (s, 1H, N=CH), 
7.72 (s, 1H, CH), 6.86-7.52 (m, 9H, Ar-H), 
1.45 (s, 3H, CH3); 13C NMR (75 MHz, DMSO- 
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Table 1: Physical data of synthesized compounds 3a-3l and 4a-4l. 
 







3a -H -H 62 140 C17H13N3S2 
3b -H 2-Cl 58 144 C17H12ClN3S2 
3c -H 4-Cl 63 109 C17H12ClN3S2 
3d 4-CH3 -H 71 114 C18H15N3S2 
3e 4-CH3 2-CH3 78 132 C19H17N3S2 
3f 4-CH3 4-CH3 76 156 C19H17N3S2 
3g 4-OH -H 72 179 C17H13N3OS2 
3h 4-OH 2-OH 75 186 C17H13N3O2S2 
3i 4-OH 4-OH 78 154 C17H13N3O2S2 
3j 4-N(CH3)2 -H 76 156 C19H18N4S2 
3k 4-N(CH3)2 2-OCH3 72 179 C20H20N4OS2 
3l 4-N(CH3)2 4-OCH3 66 141 C20H20N4OS2 
4a -H -H 67 158 C19H15N3OS3 
4b -H 2-Cl 61 163 C19H14ClN3OS3 
4c -H 4-Cl 65 129 C19H14ClN3OS3 
4d 4-CH3 -H 71 136 C20H17N3OS3 
4e 4-CH3 2-CH3 73 146 C21H19N3OS3 
4f 4-CH3 4-CH3 74 156 C21H19N3OS3 
4g 4-OH -H 71 167 C19H15N3O2S3 
4h 4-OH 2-OH 73 123 C19H15N3O3S3 
4i 4-OH 4-OH 75 167 C19H15N3O3S3 
4j 4-N(CH3)2 -H 70 189 C21H20N4OS3 
4k 4-N(CH3)2 2-OCH3 71 134 C22H22N4O2S3 
4l 4-N(CH3)2 4-OCH3 67 156 C22H22N4O2S3 
 
Table 2: Antitubercular activity and docking score of compounds 3a-3l 
 
Compound R1 R2 MIC 
(μg/mL) PDB code 
E score           
(kJ/ mol) 
3a -H -H 12.5 2YES -139.92 
3b -H 2-Cl 6.25 2YES -144.60 
3c -H 4-Cl 6.25 2YES -144.60 
3d 4-CH3 -H 12.5 2YES -143.75 
3e 4-CH3 2-CH3 6.25 2YES -145.74 
3f 4-CH3 4-CH3 3.125 2YES -145.74 
3g 4-OH -H 12.5 2YES -138.60 
3h 4-OH 2-OH 3.125 2YES -144.07 
3i 4-OH 4-OH 3.125 2YES -144.07 
3j 4-N(CH3)2 -H 6.25 2YES -145.62 
3k 4-N(CH3)2 2-OCH3 6.25 2YES -147.61 
3l 4-N(CH3)2 4-OCH3 6.25 2YES -147.61 
Streptomycin - - 6.25 2YES -125.43 
Pyrazinamide - - 3.12 2YES -123.07 
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Table 3: Antitubercular activity and docking score of compounds 4a-4l 
 
Compound R1 R2 MIC 
(μg/mL) PDB code 
E score           
(kJ/ mol) 
4a -H -H 6.25 2YES -147.51 
4b -H 2-Cl 3.12  2YES -147.31 
4c -H 4-Cl 3.12  2YES -147.31 
4d 4-CH3 -H 6.25 2YES -147.53 
4e 4-CH3 2-CH3 3.12 2YES -146.04 
4f 4-CH3 4-CH3 1.6 2YES -146.04 
4g 4-OH -H 6.25 2YES -146.99 
4h 4-OH 2-OH 3.12 2YES -147.00 
4i 4-OH 4-OH 1.6 2YES -147.00 
4j 4-N(CH3)2 -H 6.25 2YES -146.01 
4k 4-N(CH3)2 2-OCH3 3.12 2YES -146.62 
4l 4-N(CH3)2 4-OCH3 3.12  2YES -146.62 
Streptomycin - - 6.25 2YES -125.43 
Pyrazinamide - - 3.12 2YES -123.07 
 
 
d6 ): δ 32.65, 43.74, 130.60, 134.86, 140.93, 
144.85, 150.86, 153.55, 160.17, 160.68, 
163.23, 164.40;MS spectrum, m/z: 338 [M+1] 
+; Anal. Calcd for C18H15N3S2 : C (64.06), H 
(4.48), N (12.45). Found: C (64.01), H (4.44) 




b][1,3,4] thiadiazol-2-amine (3e): FTIR 
(KBr) cm-1: 3108 (Ar C-H), 2950(C-H), 2870 
(C-H thiazole), 1585 (-N=CH), 712 (C-S-C); 
1H NMR chemical shifts at ( 400 MHz, CDCl3, 
δ ppm): 10.16 (s, 1H, CH), 8.39 (s, 1H, 
N=CH), 7.86 (s, 1H, CH), 7.25-7.63 (m, 8H, 
Ar-H), 2.45 (s, 6H, CH3); MS spectrum, m/z: 




b][1,3,4] thiadiazol-2-amine (3f): FTIR (KBr) 
cm-1: 3005 (Ar C-H), 2890 (C-H), 2750 (C-H 
thiazole), 1583 (-N=CH), 712 (C-S-C); 1H 
NMR chemical shifts at ( 400 MHz, CDCl3, δ 
ppm): 10.14 (s, 1H, CH), 8.36 (s, 1H, N=CH), 
7.81 (s, 1H, CH), 7.22-7.68 (m, 8H, Ar-H), 





(3g): FTIR (KBr) cm-1: 3545 (O-H), 3005 
(ArC-H), 2955 (C-H),  2875 (C-H thiazole), 
1515 (-N=CH), 695 (C-S-C); 1H NMR 
chemical shifts at ( 400 MHz, CDCl3, δ ppm): 
9.63 (s, 1H, CH), 7.83 (s, 1H, CH), 8.19 (s, 
1H, N=CH), 7.18-7.34 (m, 9H, Ar-H), 5.28 (s, 




phenol (3h): FTIR (KBr) cm-1: 3515 (O-H), 
3005 (Ar C-H), 2965 (C-H), 2885 (C-H 
thiazole), 1550 (-N=CH), 702 (C-S-C); 1H 
NMR chemical shifts at ( 400 MHz, CDCl3, δ 
ppm): 9.82 (s, 1H, CH), 7.95 (s, 1H, CH), 
8.22 (s, 1H, N=CH), 7.05-7.45 (m, 8H, Ar-H), 





5-yl)phenol (3i): FTIR (KBr) cm-1: 3530 (O-
H), 3005 (ArC-H), 2955 (C-H), 2875 (C-H 
thiazole), 1535 (-N=CH), 780 (C-S-C); 1H 
NMR chemical shifts at ( 400 MHz, CDCl3, δ 
ppm): 9.85 (s, 1H, CH), 7.98 (s, 1H, CH), 
8.30 (s, 1H, N=CH), 7.10-7.38 (m, 8H, Ar-H), 
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thiadiazol-2-amine (3j): FTIR (KBr) cm-1: 
3111 (Ar C-H), 2962 (C-H), 2875 (C-H 
thiazole), 1583 (-N=CH), 714 (C-S-C); 1H 
NMR chemical shifts at ( 400 MHz, CDCl3, δ 
ppm): 9.86 (s, 1H, CH), 9.39 (s, 1H, N=CH), 
6.34 (s, 1H, CH), 7.17-7.72 (m, 9H, Ar-H), 
1.42-1.47(s, 6H, CH3); MS spectrum, m/z: 




[4,3-b] [1,3,4]thiadiazol -2-amine (3k): FTIR 
(KBr) cm-1: 3120 (Ar C-H), 2965 (C-H), 2892 
(C-H thiazole), 1585 (-N=CH), 718 (C-S-C); 
1H NMR chemical shifts at ( 400 MHz, CDCl3, 
δ ppm): 9.92 (s, 1H, CH), 9.28 (s, 1H, N=CH), 
6.37 (s, 1H, CH), 7.80-7.95 (m, 8H, Ar-H), 
3.15 (s, 3H, -OCH3), 1.42-1.47(s, 6H, CH3); 




[4,3-b][1,3,4] thiadiazol-2-amine (3l): FTIR 
(KBr) cm-1: 3122 (Ar C-H), 2972 (C-H), 2892 
(C-H thiazole), 1594 (-N=CH), 722 (C-S-C); 
1H NMR chemical shifts at ( 400 MHz, CDCl3, 
δ ppm): 9.80 (s, 1H, CH), 9.30 (s, 1H, N=CH), 
6.43 (s, 1H, CH), 7.75-7.98 (m, 8H, Ar-H), 
3.52 (s, 3H, -OCH3), 1.52-1.58(s, 6H, CH3); 




one(4a): FTIR (KBr) cm-1: 3121 (Ar C-H); 
2972 (C-H); 2877 (C-H thiazole); 1692 (-
C=O), 705 (C-S-C). 1H NMR chemical shifts 
at ( 400 MHz, CDCl3, δ ppm): 11.21 (s, 1H, 
CH); 7.82 (s, 1H, CH); 7.28-7.58 (m, 10H, Ar-
H); 4.11 (s, 1H, -N-CH), 4.08 (s, 2H, SCH2);  
MS spectrum, m/z: 399[M+1] +; Anal. Calcd. 
for C19H15N3OS3: C (57.40), H (3.80), N 





thiazolidin-4-one (4b): FTIR (KBr) cm-1:  
3112 (Ar C-H); 2950 (C-H); 2870 (C-H 
thiazole); 1685 (-C=O), 703 (C-S-C), 761 (-C-
Cl). 1H NMR chemical shifts at ( 400 MHz, 
CDCl3, δ ppm): 11.11 (s, 1H, CH); 7.92 (s, 
1H, CH); 7.35-7.75 (m, 9H, Ar-H) 4.12 (s, 1H, 
-N-CH), 4.17 (s, 2H, SCH2); MS spectrum, 




thiazolidin-4-one (4c): FTIR (KBr) cm-1: 
3115 (Ar C-H); 2972 (C-H); 2869 (C-H 
thiazole); 1674 (-C=O), 710 (C-S-C), 755 (-C-
Cl). 1H NMR chemical shifts at ( 400 MHz, 
CDCl3, δ ppm): 11.09 (s, 1H, CH); 7.76 (s, 
1H, CH); 7.30-7.70 (m, 9H, Ar-H); 4.10 (s, 
1H, -N-CH), 4.18 (s, 2H, SCH2); MS 




thiazolidin-4-one (4d): FTIR (KBr) cm-1:  
3153 (Ar C-H); 2928 (C-H); 2358 (C-H 
thiazole); 1693 (-C=O), 723 (C-S-C). 1H NMR 
chemical shifts at ( 400 MHz, CDCl3, δ ppm): 
10.05 (s, 1H, CH); 7.87 (s, 1H, CH); 7.21-
7.24 (m, 9H, Ar-H); 2.84 (s, 3H, CH3); 4.44 (s, 
1H, -N-CH), 4.72 (s, 2H, SCH2); 13C NMR (75 
MHz, DMSO-d6 ): δ 28.02, 28.27, 28.32, 
32.87, 37.26, 128.93, 130.60, 132.44, 
137.26, 140.97, 144.65, 153.55, 160.17, 
160.68, 163.33, 164.43, 177.97;  MS 
spectrum, MS spectrum, m/z: 412 [M+1] +; 
Anal. Calcd. for C20H17N3OS3: C (58.37), H 
(4.16), N (10.21). Found: C (58.31), H (4.14) 





one (4e): FTIR (KBr) cm-1: 3110 (Ar C-H); 
2960 (C-H); 2880 (C-H thiazole); 1685 (-
C=O), 669 (C-S-C). 1H NMR chemical shifts 
at ( 400 MHz, CDCl3, δ ppm): 10.16 (s, 1H, 
CH); 7.86 (s, 1H, CH); 7.32-7.63 (m, 8H, Ar-
H); 2.74 (s, 6H, CH3); 4.06 (s, 1H, -N-CH), 
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4.19 (s, 2H, SCH2);  MS spectrum, MS 





one (4f): FTIR (KBr) cm-1: 3153 (Ar C-H); 
2980 (C-H); 2895 (C-H thiazole); 1748 (-
C=O), 713 (C-S-C). 1H NMR chemical shifts 
at ( 400 MHz, CDCl3, δ ppm): 10.15 (s, 1H, 
CH); 7.81 (s, 1H, CH); 7.32-7.48 (m, 8H, Ar-
H); 2.24 (s, 6H, CH3); 4.12 (s, 1H, -N-CH), 
4.30 (s, 2H, SCH2);  MS spectrum, MS 




thiazolidin-4-one (4g): FTIR (KBr) cm-1: 
3545 (O-H); 3005 (Ar C-H); 2955 (C-H); 2875 
(C-H thiazole); 1738 (-C=O), 675 (C-S-C). 1H 
NMR chemical shifts at ( 400 MHz, CDCl3, δ 
ppm): 9.63 (s, 1H, CH); 7.83 (s, 1H, CH); 
7.18-7.34 (m, 9H, Ar-H); ; 5.28 (s, 1H, OH); 
4.15 (s, 1H, -N-CH), 4.19 (s, 2H, SCH2); MS 





one (4h): FTIR (KBr)  cm-1: 3515 (O-H); 3005 
(Ar C-H); 2955 (C-H); 2875 (C-H thiazole); 
1750 (-C=O), 705 (C-S-C). 1H NMR chemical 
shifts at ( 400 MHz, CDCl3, δ ppm): 9.63 (s, 
1H, CH); 7.83 (s, 1H, CH); 7.28-7.44 (m, 8H, 
Ar-H); 5.20 (s, 2H, OH); 4.10 (s, 1H, -N-CH), 






one (4i): FTIR (KBr) cm-1: 3530 (O-H); 3005 
(Ar C-H); 2955 (C-H); 2875 (C-H thiazole); 
1738 (-C=O), 715 (C-S-C). 1H NMR chemical 
shifts at ( 400 MHz, CDCl3, δ ppm): 9.63 (s, 
1H, CH); 7.83 (s, 1H, CH); 7.32-7.54 (m, 8H, 
Ar-H); 5.28 (s, 2H, OH); 4.11 (s, 1H, -N-CH), 





phenyl-1,3-thiazolidin-4-one (4j): FTIR 
(KBr) cm-1: 3105 (Ar C-H); 2945 (C-H); 2785 
(C-H thiazole); 1695 (-C=O), 703 (C-S-C). 1H 
NMR chemical shifts at ( 400 MHz, CDCl3, δ 
ppm): 9.84 (s, 1H, CH); 6.36 (s, 1H, CH); 
7.39-7.72 (m, 9H, Ar-H); 1.42-1.47(s, 6H, 
CH3); 4.18 (s, 1H, -N-CH), 4.25 (s, 2H, 





one(4k): FTIR (KBr) cm-1: 3095 (Ar C-H); 
2895 (C-H); 2760 (C-H thiazole); 1675 (-
C=O), 675 (C-S-C). 1H NMR chemical shifts 
at ( 400 MHz, CDCl3, δ ppm): 9.77 (s, 1H, 
CH); 6.45 (s, 1H, CH); 7.80-7.95 (m, 8H, Ar-
H); 3.15 (s, 3H, -OCH3); 1.42-1.47(s, 6H, 
CH3); 4.13 (s, 1H, -N-CH), 4.21 (s, 2H, 





one  (4l): FTIR (KBr) cm-1: 3105 (Ar C-H); 
2925 (C-H); 2880 (C-H thiazole); 1666 (-
C=O), 708 (C-S-C). 1H NMR chemical shifts 
at ( 400 MHz, CDCl3, δ ppm): 9.67 (s, 1H, 
CH); 6.49 (s, 1H, CH); 7.66-7.89 (m, 8H, Ar-
H); 3.55 (s, 3H, -OCH3); .1.40-1.49(s, 6H, 
CH3); 4.05 (s, 1H, -N-CH), 4.19 (s, 2H, 




The synthesized compounds showed good 
docking score compared to the standard 
drugs, streptomycin and pyrazinamide. 
Tabulation of ligands docking score for 3a-l 





The synthesized compounds showed higher 
in vitro activity than the standard drugs, 
streptomycin and pyrazinamide. In the Schiff 
base series 3a-l, compounds 3f, 3h and 3i  
Malipeddi et al 
Trop J Pharm Res, August 2012;11 (4): 619 
showed good antitubercular activity 
compared to streptomycin. In the 
Thiazolidinone series 4a-l, compounds 4f and 
4i showed higher antitubercular activity than 
both pyrazinamide and streptomycin; 
compounds 4b, 4c, 4e, 4h, 4k, 4l showed 
similar activity to pyrazinamide but they all 




FTIR, 1H-NMR, 13C-NMR and mass spectra 
are in agreement with the proposed 
structures. All synthesized compounds 
showed good docking score compared to the 
standard drugs while the thiazolidinone series 
showed better docking scores than the Schiff 
base series. This suggests that cyclisation 
increases the docking scores. A closer look 
at the anti-tubercular results reveals that in 
Schiff base series (3a-l), increasing the 
substitution on nitrogen gave better activity 
(4a-l), perhaps due to increase in 
hydrophobicity resulting in better penetration 
of the Mtb cell wall. The structure - activity 
relationship of the compounds show that the 
presence of pharmacophoric moieties such 
as 1,3,4-thiadiazole nucleus (thiazolidinone 
moiety), increases antitubercular activity. A 
substituent, such as 4-methyl, 4-hydroxy 
group, attached to the phenyl ring and 
increases the substitution on nitrogen (NH2 
group) with thiazolidinone moiety to give 
higher activity, perhaps due to increase in 
hydrophobicity resulting in better penetration 




The overall outcome of these results reveals 
that thiazolidinone ring is a satisfactory 
backbone for antitubercular activity. These 
preliminary buy encouraging anti-tubercular 
results could offer an excellent framework in 
the field that may lead to the discovery of 
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